Posts tagged Piper Jaffray
Analysts start Tactile Systems at buy, outperform

Analysts at BTIG Research, Piper Jaffray and William Blair initiated coverage of Tactile Systems Technology (NASDAQ:TCMD) with “buy,” “overweight” and “outperform” ratings, respectively.

Tactile makes pneumatic compression devices (PCD) to treat lymphedema, along with a chronic venous leg ulcer product. Tactile closed an IPO of 4,120,000 shares at $10 apiece earlier this month. The stock was changing hands at $12.98 at mid-day Monday.

Read More
Piper starts ReWalk Robotics at overweight

Piper Jaffray initiated coverage of ReWalk Robotics (NASDAQ:RWLK) with an “overweight” rating and price target of $10. The stock closed at $7.02 on Thursday.

“While the exoskeleton market for personal use is in what we would categorize as the market creation phase, which carries a higher degree of risk and volatility, we believe ReWalk has the first mover advantage, best technology and a solid business plan to further penetrate this large, relatively untapped market,” writes analyst Matt O’Brien.

Read More
Piper Jaffray starts Inogen at neutral

Piper Jaffray has initiated coverage of Inogen (NASDAQ:INGN) with a “neutral” rating and price target of $46. The stock closed at $41.07 on Wednesday.

“We truly appreciate the unique technology the company has developed – portable oxygen concentrators (POCs) – and believe it will continue delivering solid top-line growth in the coming years,” writes analyst Matt O’Brien.

Read More
Shaunak Deepak joins H.C. Wainwright

Shaunak Deepak has joined H.C. Wainwright as a managing director and senior biotechnology analyst in the firm’s equity research group.

Mr. Deepak previously was a VP and biotech analyst with Jefferies since 2009. He also has been an associate in the life sciences equity research departments of Piper Jaffray, Rodman & Renshaw and Stifel, Nicolaus.

Read More